This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.89% per year. These returns cover a period from January 1, 1988 through March 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Celebrate Thanksgiving Week With These ETFs
by Sweta Killa
Thanksgiving week is here and history shows that this holiday-shortened week is a bullish feast for stock investors.
Should You Invest in the U.S. Global Jets ETF (JETS)?
by Zacks Equity Research
Sector ETF report for JETS
ETF Strategies to Play as Vaccine Hopes Firm With Moderna Data
by Sanghamitra Saha
It???s been really a sweet November for the global economy and markets thanks to back-to-back release of upbeat coronavirus vaccine data from Moderna and Pfizer.
Leisure Stocks & ETFs Rally on Strong Vaccine Hopes
by Sanghamitra Saha
Hopes of a sooner-than-expected coronavirus vaccine launch led Wall Street to a record high on Nov 16 .
Biggest ETF Winners from Coronavirus Vaccine News
by Neena Mishra
Promising vaccine results from Pfizer sent economically sensitive stocks soaring
ETFs Riding the Latest Coronavirus Vaccine Optimism Wave
by Sweta Jaiswal, FRM
The coronavirus vaccine progress has brought back optimism for some ETFs, which were largely affected by the outbreak-led slowdown in economic activities.
Vaccine Hopes & Divided Government: Sector ETFs to Win
by Sanghamitra Saha
News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has instilled more optimism in the markets.
5 ETFs Up Double Digits in a Day on Vaccine Optimism
by Sanghamitra Saha
Wall Street soared on Nov 9 on news that Pfizer (PFE) and BioNTech (BNTX) vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial.
Should You Invest in the First Trust NASDAQ Transportation ETF (FTXR)?
by Zacks Equity Research
Sector ETF report for FTXR
Should You Invest in the U.S. Global Jets ETF (JETS)?
by Zacks Equity Research
Sector ETF report for JETS
Top ETF Stories of the Volatile October
by Sanghamitra Saha
October 2020 saw some solid stock market gyrations due to election uncertainty and rising virus cases.
Should You Invest in the First Trust NASDAQ Transportation ETF (FTXR)?
by Zacks Equity Research
Sector ETF report for FTXR
Will Coronavirus Vaccine & Treatment Optimism Drive These ETFs?
by Sweta Jaiswal, FRM
The coronavirus vaccine and treatment progress can bring back optimism for some ETFs, which are largely affected by the outbreak-led slowdown in economic activities.
Should You Invest in the U.S. Global Jets ETF (JETS)?
by Zacks Equity Research
Sector ETF report for JETS
5 Top-Performing ETFs of Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones and the Nasdaq Composite lost about 0.5%, 1% and 1.1%, respectively, in the past week.
Should You Invest in the First Trust NASDAQ Transportation ETF (FTXR)?
by Zacks Equity Research
Sector ETF report for FTXR
Airline ETF Rallies on a Slew of Positive News
by Sweta Killa
Airline stocks have showed strength this week buoyed by rounds of positive news. First, the uptick in air travel demand led to a spike and then President Trump's support for the industry's federal aid program.
ETFs to Gain Despite Stalled Stimulus Talks
by Sanghamitra Saha
In the latest development on the ongoing U.S. fiscal stimulus negotiations, President Donald Trump unexpectedly stalled virus-related relief talks until after the election.
Should You Invest in the U.S. Global Jets ETF (JETS)?
by Zacks Equity Research
Sector ETF report for JETS
Top ETF Stories of September
by Sanghamitra Saha
After a sturdy August, Wall Street suffered in September, marking the worst September since 2011.
ETFs Winners & Losers to Start Another Rough Week
by Sweta Killa
The weak trading on Sep 21 led to a few winners with low-risk products but a number of losers from various corners of the investing space.
Should You Invest in the First Trust NASDAQ Transportation ETF (FTXR)?
by Zacks Equity Research
Sector ETF report for FTXR
Should You Invest in the U.S. Global Jets ETF (JETS)?
by Zacks Equity Research
Sector ETF report for JETS
Is It Again Time to Shift Focus to Cyclical ETFs?
by Sanghamitra Saha
AstraZeneca has restarted British clinical trials of its COVID-19 vaccine. This piece of information may help boost cyclical ETFs all over again.
Don't Fear Correction: ETF Laggards Are Emerging Leaders
by Sanghamitra Saha
U.S. stocks were super steady in August as investors rotated into the beaten-down segments of the year ??? cyclicals.